Keywords
Human papillomavirus · Genital dysplasia · Crohn’s disease · TNF-α blockers

Abstract
Background: Young patients with Crohn’s disease (CD) show a high prevalence of human papillomavirus (HPV) which is the main cause of high-grade squamous intraepithelial lesions (HSIL). A major complication for patients undergoing immunocompromising therapy is the development of genital dysplasia. Methods: We report the case of a 32-year-old patient with recurrent genital dysplasia under long-term therapy for CD with a focus on different drug-related, immunosuppressive mechanisms. Results: Gynecological examination and biopsy revealed high-grade vulvar intraepithelial neoplasia (VIN) positive for HPV 16 treated with laser vaporization. Due to the combination of HPV positivity, intraoperative multilocularity, and CD, follow-up examinations were performed every 6 months. One year later, the patient showed a VIN at a new location and additionally, a cervical intraepithelial neoplasia (CIN), which were surgically treated. Catch-up HPV vaccination was applied accessosily. After the switch from a TNF-α blocker to vedolizumab, which acts as a gut-selective anti-integrin, the subsequent PAP smear, vulvoscopy, and colposcopy showed no more evidence of dysplasia. Conclusions: This case report highlights that gut-selective immunosuppression with vedolizumab might be favorable in young HPV-positive patients due to a good side effect profile. Regular screening and HPV vaccination are a mainstay of dysplasia prevention and control. The risk for HPV-associated dysplasia in immunosuppressed patients is highly dependent on the choice of immunosuppressive therapy.

Introduction
Around 80% of sexually active adults will acquire a human papillomavirus (HPV) infection at least once in their lifetime. The highest prevalence of HPV infection in the female genital tract (up to 30%) is found in 15 to 25-year-old females due to a low immunization rate and the frequent switching of sexual partners relative to older age groups [1–3]. HPV is associated with several genital malignant cancer precursors including cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VAIN), and anal intraepithelial neoplasia (AIN). These precancerous lesions are differentiated into low- and high-grade squamous intraepithelial lesions (LSIL, HSIL) [4–6]. The host immune system usually clears an HPV infection successfully.
Patients with immunosuppressive drugs have an increased risk for persistent infections and progression to intraepithelial neoplasia [7]. The neoplasia risk differs depending on both the underlying disease and the mechanism of action of the immunosuppressant. In Crohn’s disease (CD), which is one of the two main forms of inflammatory bowel disease, currently used immunosuppressive therapies include glucocorticosteroids, methotrexate, thiopurines, and biologicals. The most frequently used biologicals are tumor necrosis factor (TNF)-α blockers, ustekinumab and vedolizumab. Vedolizumab is a fully humanized monoclonal antibody that specifically blocks the migration of a subset of leukocytes harboring the αβ47 integrin into inflamed intestinal tissue via MAdCAM-1. Those biologicals which work against cytokines or cell surface antigens are very potent therapeutics against autoimmune diseases, inflammatory diseases, and tumors. However, these biologicals can also induce adverse reactions including autoimmunity as well as bacterial, viral, or fungal infections [8, 9]. Patients with HPV infection and inflammatory bowel disease have an increased prevalence for genital dysplasia [10–14].

We aim to raise awareness of immunosuppression-associated and HPV-induced genital dysplasia and discuss possible pathomechanisms.

Materials and Methods

We describe the case of a 32-year-old female patient who was diagnosed with CD at the age of 22 years. We consider the patient’s history, the course of the disease with a focus on the occurrence of genital dysplasia, and the clinical findings in colposcopy and histology. Different conservative and surgical treatments are discussed, with a focus on the role of the immunosuppressive side effects of the currently used biologicals. Recommendations for the follow-up care and disease management for young, female patients with CD are derived from both the presented clinical findings and from a review of the literature.

Results

The 32-year-old patient had a 10-year history of CD and presented with unilateral vulvar edema 8 years after the first CD manifestation. Initial CD manifestation was
a terminal ileitis, left-sided colitis, and perianal activity. For the first 5 years following the diagnosis, the patient received several immunosuppressive agents including glucocorticosteroids, thiopurines (short-term for 3–4 weeks in the first and fifth year of the disease; not tolerated due to adverse events such as headache, nausea, and arthralgia), and TNF-α blockers including 2 years of infliximab treatment, 2 years of adalimumab treatment, and 3 months of certolizumab pegol treatment (Fig. 1). Due to a steroid-refractory ileus, a laparoscopic ileocecal resection was performed at age 27 with postoperative complications. The recovery after the laparoscopic ileocecal resection was complicated due to anastomotic leakage of the ileo-transverse anastomosis, a fistula of the small bowel 50 cm after the angle of Treitz, a stomal stenosis, and an abscess in the right lower abdomen requiring two subsequent laparotomies. Due to an early CD relapse, golimumab was given as a fourth TNF-α blocker for 2 years (which it must be stated is an off-label treatment since golimumab is licensed for ulcerative colitis only). After 8 years of CD and after years of immunosuppression including thiopurines and four different TNF-α blockers, the patient developed a swelling of the left labium majus. An MRI showed no evidence of underlying fistulizing CD or granulomatous subcutaneous disease. The patient was bothered by the swelling which led to her avoiding sexual activity.
intercourse in a stable relationship. The patient was admitted to the gynecological outpatient clinic to rule out an immunosuppression-associated complication (infection or cancer). There was no evidence of an infectious disease. The size of the edema was demarcated by the left labium majus, and measured approximately 7.8 × 3.2 × 0.4 cm (Fig. 2a). A vulvo-colposcopy was performed with the application of aqueous 5% acetic acid (Fig. 2b). A punch biopsy of the left labium minus was taken from an aceto-positive discrete keratosis that histologically showed a high-grade lesion (VIN III), which was HPV 16 positive (Fig. 2b). In this examination, the VIN was detected as an incidental finding but as a potentially malignant disease. No biopsy was undertaken from the soft, smooth, and even edema, as no genital granulomatosis was clinically suspected in the pelvic MRI. Elephantiasis with filarial parasites did not align with the personal history. As the edema was self-limiting and did not recur, no further edema-specific examinations were considered necessary.

A lymphedema of the left labium majus was postulated due to several abdominal surgeries (Fig. 2a). However, the last abdominal surgery (a colonic resection of the transverse colon and a reversal of an ileal stoma) had been performed 3 years previously.

In the subsequent surgery, VIN III was intraoperatively excised on both sides of the labium minus, and a biopsy in the introitus revealed a further low-grade intra-squamous lesion (VIN I, LSIL). Histological examination showed dysplasia-free margins (R0). Laser vaporization of the surroundings of the vulvar lesions and introital biopsy were performed. The immunosuppression with golimumab as a fourth TNF-α blocker was continued due to the lack of alternatives at that time. The follow-up examination after 6 months was unremarkable. Another 6 months later, the follow-up examination showed a high-grade VIN (VIN II–III) lesion at the left labium majus, in the posterior part, without edema (Fig. 2c). Therefore, a fusiform excision of the left labium major, a perineal biopsy, laser vaporization of the vulva, a punch biopsy of the cervix, and an anoscopy were carried out (Fig. 2d).

Histology of the cervix also revealed an HSIL (Fig. 2e, f), that was removed by the loop electrosurgical excision (LEEP) procedure. Additionally, an HPV catch-up vaccination with the quadrivalent agent Gardasil was administered [15]. At that time, the immunosuppressive agent was switched to vedolizumab as a gut-selective immunosuppressive agent, which had newly become available in Switzerland.

Follow-up examinations carried out over the following 21 months, and while using the vedolizumab-based treatment, showed no further abnormalities in either the PAP smears or in the aceto-white testing. At age 32, and 1.5 years after the first VIN treatment, the patient became pregnant. After two miscarriages, both in the first trimester, the third pregnancy took an obstetrically normal course. Colposcopic and cytological examinations did not reveal any dysplasia. Continued treatment with vedolizumab and mesalazine before pregnancy and in the first trimester of pregnancy could not prevent a small intestinal ileus due to fibrostenotic CD. A second small intestinal resection (17.5 cm) with post-operative anastomotic leakage and ileostomy was performed in the second trimester. Despite all the medication and surgical complications, the patient delivered a healthy baby in the 37th gestational week (2,770 g, 46 cm).

Discussion

CD is a chronic inflammatory bowel disease affecting young patients [16]. CD often coincides with the fertile phase which is also the most vulnerable phase for HPV infections [3]. This case study supports previous studies that highlighted the role of immunosuppressive agents in the development of multilocular genital dysplasia in CD patients [17–19], while providing new insight into the beneficial role of a gut-selective immunosuppression therapy.

CD itself may be associated with a greater risk of genital dysplasia, especially for VIN [12, 18]. Immunosuppressive treatments, which are necessary in most patients, may additionally have an impact on infection risk and HPV progression. Azathioprine increases the risk of genital dysplasia in a dose-dependent manner [20]. In our patient the high-grade lesions occurred under longstanding therapy with different TNF-α blockers (Fig. 2). Genital dysplasia has been described after the use of TNF-α blockers [21, 22]. TNF-α plays an important role in the immune response to infections. After application of anti-TNF-α monoclonal antibodies, activated T lymphocytes and macrophages fall into apoptosis in vivo [23–25]. Literature concerning HPV infections under TNF-α blockers is scarce. However, it has been shown that HPV-specific CD4+ and CD8+ T cells are important for long-term tumor protection [26]. We assume that the immunosuppression played an important role in the rapid progression of the condition to genital high-grade dysplasia.
at a young age and to the de novo occurrence of high-grade lesions at different sites.

The most interesting finding of our case, however, is that the HPV-associated precancerous lesions disappeared in a follow-up performed 2 years after the switch from unselective immunosuppression with TNF-α blockers to the gut-selective antibody vedolizumab. Careful follow-up controls with PAP smears and vulvo-colposcopy including aceto-white testing were normal. Vedolizumab shows a strong or intense binding capacity to the small intestine and colon, respectively, as the main targets for CD treatment [27, 28], but no or only a weak binding capacity to the skin (vulva) and the cervix, respectively [20]. Our findings suggest that, in the context of genital dysplasia, it is favorable to use either inflammatory bowel disease treatments that are less immunosuppressive (avoiding TNF-α blockers) or specific immunosuppressive treatments (including the gut-selective antibody vedolizumab).

Other potentially relevant risk factors for a more rapid disease progression are age over 25 years, HSIL of the cervix, and a history of an HPV type 16 infection [29]. The occurrence and recurrence of genital dysplasia in our case were certainly influenced by these different risk factors.

Routine PAP smears are performed every 3 years in the base Swiss population. In the context of female CD patients, the ECCO guidelines strongly recommend regular gynecologic screening for cervical cancer, especially if the patient is also being treated with immunosuppressive/immunomodulating drugs. Our case highlights that gynecologic screening in CD patients should include careful vulvoscopy to exclude VIN as well. We propose an annual screening for CD patients (PAP smear plus HPV PCR) as well as a vulvo-colposcopy of the anogenital region with aceto-white testing for the early detection of anogenital lesions. In the case of posttreatment, we propose follow-up visits every 6 months.

The initial vulvar edema was self-limiting in our patient. In the literature the underlying pathomechanism of vulvar edema is described as a chronic granulomatous inflammation of the skin which is one of the extra-intestinal manifestations of CD [30]. However, histologies in our patient showed no evidence of dermal epithelioid granulomas.

Based on the gynecological findings and locations, as seen in Figure 1, the treatment had to be individually adjusted since laser vaporization, excision, and conization have different risk profiles. To find the suitable treatment choice, the staging of the lesion, the age of the patient, and the cytology should all be considered [31].

For instance, cervical conization needs to be highlighted in the context of this case, since our patient had a desire to become pregnant. This is due to the fact that the height of the conus has a major impact on the risk of preterm delivery. A significant increase for preterm delivery was found at a conus height of 1.5 cm. The LEEP procedure showed the best outcome (lowest risk) regarding a preterm delivery and is therefore the gold standard [32, 33]. Standard practice in preconception counseling after a conization with dysplasia-free margins (R0) is to defer pregnancy for 6 months in order to prove a negative PAP smear.

The additional quadrivalent HPV vaccination after the conization was performed to improve the outcome after the different surgical treatments and also to improve the patient’s immunity. The determinant factor for this approach is a proven lower relapse rate of about 35.2% [34]. Vaccination might have contributed to the favorable follow-up. There are three currently available vaccines: davalent targeting HPV 16/18, quadrivalent targeting HPV 6/11/16/18, and nonvalent targeting the aforementioned types as well as HPV types 31/33/45/51/58. The vaccines demonstrated a potential to prevent 70% of cervical cancer within an adequately vaccinated population. In the future, it is expected that the nonvalent vaccines achieve an 85–95% protection against VIN and a 90% protection against CIN [35, 36]. The American Society for Colposcopy and Cervical Pathology (ASSCP) recommends that the most effective primary prevention is to vaccinate girls before they become sexually active [37].

A better understanding of the pathways of HPV infection and immunity is crucial in order to be able to develop individualized recommendations. Given the fact that there is still a knowledge gap, HPV vaccination of immunocompromised patients and patients with an iatrogenic immunocompromising therapy is crucial. Various immunosuppressive agents including biosimilars have to be followed meticulously regarding their effects on genital dysplasia in order to prevent cervical, vulvar, vaginal, or anal cancer.

**Conclusion**

Our case study demonstrated the recurrence of HPV-associated multilocular genital dysplasia under TNF-α blockers. The genital dysplasia was detected due to a good collaboration between different medical specialties. The early detection in combination with an individualized therapy including surgery, vaccination, and adjustment of immunosuppression therapy led to a favorable outcome.
Genital Dysplasia: Importance of Organ-Specific Therapy

Statement of Ethics

Written informed consent was obtained from the patient for the publication of any data and accompanying images.

Disclosure Statement

The authors declare that they have no competing interests.

Pascal Frei has received consulting fees from MSD, AbbVie, and Takeda and travel grants from Vifor Pharma. Takeda, which is marketing vedolizumab, was not involved in this case report and had thus no influence on the paper.

References

3 Remschmidt C, Fesenfeld M, Kaufmann AM, the publication of any data and accompanying images.

Inflamm Intest Dis 2019;4:154–160
DOI: 10.1159/000502687